AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Up 8.6% in November

by · The Cerbat Gem

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 6,710,000 shares, a growth of 8.6% from the October 31st total of 6,180,000 shares. Based on an average trading volume of 403,100 shares, the days-to-cover ratio is presently 16.6 days. Currently, 25.8% of the shares of the stock are short sold.

Analysts Set New Price Targets

Several brokerages have weighed in on ANAB. UBS Group boosted their price target on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. dropped their target price on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday. Truist Financial lifted their price target on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Finally, Guggenheim increased their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $54.64.

Check Out Our Latest Research Report on ANAB

AnaptysBio Trading Down 2.3 %

NASDAQ:ANAB opened at $24.38 on Tuesday. The firm’s fifty day simple moving average is $27.91 and its 200 day simple moving average is $29.74. AnaptysBio has a twelve month low of $14.70 and a twelve month high of $41.31. The firm has a market capitalization of $741.88 million, a price-to-earnings ratio of -4.01 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. On average, analysts predict that AnaptysBio will post -6.02 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This represents a 72.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric J. Loumeau sold 8,720 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the completion of the sale, the insider now owns 7,020 shares in the company, valued at $279,536.40. This represents a 55.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently bought and sold shares of ANAB. Frazier Life Sciences Management L.P. lifted its holdings in AnaptysBio by 140.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after buying an additional 1,265,891 shares in the last quarter. FMR LLC increased its position in shares of AnaptysBio by 15.3% during the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after acquiring an additional 438,557 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of AnaptysBio during the third quarter worth about $8,874,000. Victory Capital Management Inc. lifted its stake in shares of AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares during the last quarter.

About AnaptysBio

(Get Free Report)

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

Recommended Stories